Clinical Research Outsourcing in Asia - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Clinical Research Outsourcing in Asia
Increased outsourcing of clinical research in Asia is an important consideration in the pharmaceutical value chain.


PTSM: Pharmaceutical Technology Sourcing and Management
Volume 6, Issue 8

The level of clinical outsourcing in Asia is an important consideration for other elements in the pharmaceutical value chain. The increased level of clinical research in Asia has the potential to affect the supply chain of clinical trial materials (CTM), for example, by causing a potential attendant shift in CTM supply from companies based in North America and Western Europe to companies based in Asia. To what degree this shift will occur is still evolving, but it is important to consider the trends in clinical outsourcing in Asia to assess the potential impact.

Asia’s position in clinical research

A recent analysis, “Trends in Asia: Clinical Outsourcing,” by the management consulting firm PRTM examines the level of clinical research and related outsourcing activities by the large pharmaceutical companies in Asia. The report is based on a survey of sixty-five responses from the local operations of multinational pharmaceutical companies, Asia-based local pharmaceutical companies, multinational contract research organizations (CROs), and locally based CROs. The survey was conducted in the fourth quarter of 2009 and early 2010 (1).

The report shows that more than 90% of clinical trials conducted in Asia are multinational in scope. As measured by the number of multinational trials launched by the top 20 global pharmaceutical companies, South Korea, India, Taiwan, and China lead all countries in Asia (1).

Patient access is the primary rationale to increase clinical research in Asia, according to the PRTM report, but market access was also a key consideration as well as an interest in establishing long-term relationships with national regulatory authorities. Although cost was a factor, it was not cited as a significant factor in companies’ decision to conduct clinical research in Asia, according to the PRTM report (1). Survey respondents see China as the leader in being able to recruit large volumes of patients at a reasonable low cost. Although Japan is viewed as the least attractive of Asian locations for patient recruitment due to cost, it provides the highest quality data for trials. The report also cited data which showed that respondents felt that with the exception of trials in Japan, India, and South Korea, the quality of trial data in Asia is perceived to be inferior to that typical of Western countries (1).

In general, global pharmaceutical companies’ headquarters tend to lead the operations of global and multinational clinical trials remotely in all Asian countries except for Japan. Looking at activities in specific countries, taking China as an example, approximately 80% of the large pharmaceutical companies have clinical operations in China, 50% have regulatory functions, 30% have strategy and planning functions, and 30% have early-development activities. For India, 86% of the companies have clinical operations in that country, 43% have regulatory functions, and 14% have strategy and planning operations. In other countries, the level of clinical operations is lower. For example, in South Korea, 75% of the top pharmaceutical companies have clinical operations there, 50% have clinical operations in Taiwan, and 57% do in Singapore (1).

Outsourcing trends

The level of clinical outsourcing in Asia overall has increased. More than half of the multinational pharmaceutical companies surveyed currently have strategic partnerships with CROs in Asia, compared with only 20% in 2007 (1). These strategic partnerships often are formed with global CROs on a global basis, but they also involve partnerships with local companies either with the global pharmaceutical company and a local pharmaceutical company or through a global CRO subcontracting to a local CRO. According to the PRTM analysis, 65% of the large multinational pharmaceutical companies have formed co-development partnerships with local pharmaceutical companies in Asia for one or more compounds. Also, 60% of global CROS have formed alliance partnerships with local CROs in Asia (1).

A lack of internal resources and temporary increases in workload are the primary reasons for multinational pharmaceutical companies to outsource clinical research in Asia, according to the PRTM study. Seventy percent of respondents cited a lack of internal resources as the reason for outsourcing clinical research in China, and 75% cited it as a reason for outsourcing in India and Taiwan.

In looking at outsourcing activity by function, certain functions stand out in terms of the degree of outsourcing by the multinational pharmaceutical companies in Asia (excluding Japan). More than half of the respondents said that they outsource the majority (51–100%) of their workload in Asia for the following functions: data management (88% of respondents outsource the majority of their workload in this area); site monitoring and data collection (56% of respondents); biostatistical analysis (56% of respondents); site initiation and site management (56% of respondents outsource the majority of work); quality assurance and auditing (50% of respondents); and patient recruitment (50% of respondents) (1).

Most multinational pharmaceutical companies operating in Asia (excluding Japan) use a mix of global and local CROs, according to the PRTM analysis. The vast majority of multinationals take advantage of full-service outsourcing on a protocol–by-protocol basis. Full-service outsourcing generally refers to site-related activities, data management, clinical supplies, regulatory support, and pharmacovigilance (1).

Although cost, in of itself, was not a reason to outsource clinical research, the report does point out varying levels of costs among CROs. The report showed that many multinational pharmaceutical companies report that almost everywhere in Asia (except Japan), the overall cost of using local CROs is at least 40% lower than the cost of using global CROs operating in the same country. For example, 71% of survey respondents said that the cost of local CROs in China are more than 40% cheaper than the cost of global CROs in China (1).

Reference

1. PRTM, “Trends in Asia: Clinical Outsourcing,” (Tokyo, 2010).

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here